Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy

Blog Article

CD38 is a disulfide-linked molecule present on red blood cells (RBCs) and daratumumab; an anti-CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients.It also binds to the RBC along with the plasma cells ZINC-COPPER BALANCE in concern, creating a menace in the Trainning - Homme - Chaussures immunohematology workups and requires the use of dithiothreitol-treated cells to rule out its interference.Appropriate and timely communication with the clinicians about the patient history goes a long way in solving complex looking immunohematology workups.